Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in advanced squamous NSCLC (CheckMate 063)
NCT01721759Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2012
- Primary completion
- Jan 2014
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in squamous cell carcinoma of the lung (SCCL), sponsored by Bristol Myers Squibb. Primary endpoints: Objective Response Rate as Assessed by Independent Radiology Review Committee at 14 months and Duration of Response as Assessed by Independent Radiology Review Committee at 14 months. Started Nov 2012; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT01721759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721759.